PROM1 and neoplasm: Recently, a tumor-targeted photosensitizer was developed to address the insufficient targeting abilities of TTRE by conjugating a fluorescent dye to a monoclonal antibody against a tumor-specific antigen, such as EGFR [17], CD47 [18], CD44, and CD133 [19].